This database contains 211 studies, archived under the term: "Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime"
Click here to filter this large number of results.
Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations
Cummings, Jeffrey,
Emre, Murat,
Aarsland, Dag,
Tekin, Sibel,
Dronamraju, Nalina,
Lane, Roger
Hallucinations in Alzheimer’s disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson’s disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease
Wilkinson, David,
Schindler, Rachel,
Schwam, Elias,
Waldemar, Gunhild,
Jones, Roy W.,
Gauthier, Serge,
Lopez, Oscar L.,
Cummings, Jeffrey,
Xu, Yikang,
Feldman, Howard H.
Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]
Improvement of spontaneous speech in early stage Alzheimer’s with rivastigmine
Visch Brink, E. G.,
Van Rhee Temme, W.,
Rietveld, T.,
Krulder, J. W. M.,
Van Harskamp, F.,
Van der Cammen, T. J. M.
Objectives: Placebo-controlled trials have shown that rivastigmine can delay cognitive deterioration in patients with mild to moderate Alzheimer’s disease (AD). Benefits on cognitive functioning, as measured with the ADAS-Cog, occur on a daily dose of 6-12 mg when used for at least 6 months. The effect of rivastigmine on the adequacy of spontaneous speech is […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]
Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
Schmidt, Reinhold,
Alf, Claude,
Bancher, Christian,
Benke, Thomas,
Berek, Klaus,
Dal-Bianco, Peter,
Führwürth, Gerhard,
Imarhiagbe, Douglas,
Jagsch, Christian,
Lechner, Anita,
Rainer, Michael,
Reisecker, Franz,
Rotaru, Juliana,
Uranüs, Margarete,
Walter, Andreas,
Winkler, Andreas,
Wuschitz, Albert
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]